Clinical trials
Systemic Scleroderma clinical trials
Below are recruiting systemic scleroderma clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04804930Recruiting
Skin and scalp exam study in systemic scleroderma
This study uses a detailed look at your skin and scalp (often with a magnifying exam) to learn more about systemic scleroderma. It may help doctors understand the condition better and improve how it’s assessed over time.
LilleAges 18 years+ - NCT07292961Recruiting
Exercise program for people with scleroderma
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
Ankara, AltındağAges 7 years+ - NCT07343115Recruiting
Studying familial systemic scleroderma
This study looks at families where two first-degree relatives have systemic scleroderma, a rare autoimmune disease that affects the skin and organs. It aims to understand genetic and environmental factors by examining patients and their family members.
StrasbourgAges 18 years+ - NCT07641634RecruitingPhase 1/Phase 2
Testing PRO-203 for active systemic sclerosis
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
Melbourne, VictoriaAges 18–65 - NCT07182968Recruiting
Turkish questionnaire for scleroderma patients
This study is adapting a questionnaire to measure how scleroderma affects your daily life. Your responses will help make the tool more useful for Turkish-speaking patients.
Çankaya, AnkaraAges 18 years+ - NCT07090226Recruiting
Skin imaging study for diffuse scleroderma patients
This study uses a special camera (SFDI) to take painless images of your skin to see how scleroderma affects it. You may also be asked for a small skin sample (biopsy) to help understand the condition better.
Boston, MassachusettsAges 18 years+ - NCT07183072Recruiting
Scleroderma: Physical Performance and Functionality Study
This study looks at how scleroderma affects physical performance and daily function in children and adults. It aims to understand the impact of the disease on movement and everyday activities.
Çankaya, AnkaraAges 7 years+ - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT07182981Recruiting
Chewing and swallowing in scleroderma patients
This study looks at how scleroderma affects chewing and swallowing in children and adults. It aims to help understand these problems better so care can be improved.
Çankaya, AnkaraAges 7 years+ - NCT06182293Recruiting
Mouth bacteria in early systemic sclerosis
This study looks at the bacteria in the mouth (periodontal microbiota) of people with early systemic sclerosis compared to those without the condition. It may help understand if there is a link between oral health and systemic sclerosis.
StrasbourgAges 18 years+ - NCT06256575Recruiting
Diosmin for healing finger ulcers in scleroderma
This study tests whether a natural supplement called diosmin can help heal finger and toe ulcers in people with scleroderma. If you have a current ulcer that is not infected, you may be able to join.
Calgary, AlbertaAges 18 years+ - NCT07345052Recruiting
Study on systemic sclerosis in western Sweden
This study is looking at people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect internal organs) to learn more about the disease. You may join if you have been diagnosed with this condition and meet a few other requirements.
Gothenburg, SwedenAges 18 years+ - NCT07251179Recruiting
Understanding immune cells in autoimmune diseases and immune deficiencies
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
StrasbourgAges 18–70 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT05098704RecruitingPhase 2/Phase 3
Clopidogrel to help prevent systemic sclerosis in high-risk people
This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.
BayonneAges 18–85 - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
New Haven, ConnecticutAges 18–75 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT06056921RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Taiyuan, ShanxiAges 18 years+ - NCT07493395RecruitingPhase 2
CAR T-cell therapy for severe systemic sclerosis
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
LilleAges 18–64 - NCT06598982Recruiting
Muscle Weakness in the Breathing Muscles in Scleroderma
This study looks at whether people with systemic sclerosis (scleroderma) have weakness in the muscles they use to breathe. It aims to find out if measuring these muscles can help detect early breathing problems.
Konya, SelcukluAges 18–75 - NCT04265144Recruiting
Study group of adults with scleroderma for ongoing care research
This study follows adults with systemic scleroderma (also called scleroderma) to better understand the condition over time. You may be included if you meet specific diagnosis and blood-test requirements and can give informed consent.
BordeauxAges 18 years+ - NCT04356755RecruitingPhase 2
Injections under the skin to heal scleroderma finger ulcers
This Phase 2 study tests whether injections under the skin can help heal painful, poor-circulation (ischemic) finger ulcers caused by scleroderma. It is for people whose ulcers have not improved with usual care.
GrenobleAges 18 years+ - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99
Hear when a new Systemic Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Systemic Scleroderma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for systemic scleroderma?
- Yes. Clin2 currently lists 37 recruiting systemic scleroderma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic scleroderma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic scleroderma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.